Dr. Lokhorst's group explored the effects of graft vs myeloma, reporting response rates of up to 50% after infusions of donor lymphocytes.[34]The EBMT group has also performed 54 nonmyeloablative transplants.[32]While the overall mortality was high (41%), it was significantly lower (13%) ...
EP: 3.MajesTEC-1: Teclistamab in Relapsed or Refractory Multiple Myeloma EP: 4.Patient Scenario 2: A 57-Year-Old With Heavily Pretreated MM EP: 5.MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma Now Viewing EP: 6.Multiple Myeloma: Sequencing Novel Bispecific and CAR T-...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
“On one hand, (patients with multiple myeloma are) living longer, despite having an incurable disease. But on the other hand, this means requiring lifelong and often expensive medical treatments,” Djulbegovic, division of hematology-oncology, University of Pennsylvania, Perelman School of Medicine...
Understanding aspects of multiple myeloma (MM) from drug delivery to side effect management and survivorship are critical to patient management. The Advanced Clinical Educator (ACE) program in MM combined live and web-based activities to educate nurses to gain mastery of content and achieve ACE stat...
Cesar Rodriguez, MD: I want to share a case of a patient whom we saw in clinic earlier this year: a 59-year-old [woman] who presented when she first [received a diagnosis of] multiple myeloma, with radiating pain to both legs, back in 2018. And she had imaging studies by her ...
EP: 3.ASH 2023: The Most Relevant Multiple Myeloma Data Presented EP: 4.ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma EP: 5.Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma EP: 6.FDA Approves Ide-Cel in Previously Treated Multiple Myeloma ...
Multiple myeloma: a paradigm for blending community and academic care. Hematology Am Soc Hematol Educ Program. 2023;2023(1):318-323. doi:10.1182/hematology.2023000431 2. Liang EC, Sidana S. Managing side effects: guidance for use of immunotherapies in multiple myeloma. Hematology Am Soc Hematol...
Multiple Myeloma/Plasma Cell DisordersKenneth Anderson
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM EP: 3.Advances in the Treatment of High-Risk...